Biotech Investing: 3 Ways You're Doing It Wrong

Biotech investing might appear easy considering some of the big gains we've witnessed in recent years, but these three common mistakes make it very difficult for the average biotech investor to make money.

Aug 24, 2014 at 2:35PM

Lab Research
Source: Felixioncool, Pixabay

When it comes to industries that offer investors a higher than average risk-versus-reward scenario, biotech investing arguably takes the cake.

Since the benchmark S&P 500 bottomed out in March 2009 the index has gained about 200%. In contrast, SPDR S&P Biotech ETF, including dividends, has risen more than 265% over the same period. With gains of close to 800% from GW Pharmaceuticals, more than 500% from Intercept Pharmaceuticals, and a shade over 400% for Puma Biotechnology over the trailing 52 weeks, it's easy to see why biotech investing lures in so many new investors each year.

Of course, whereas this sector can create instant winners overnight, it also has the potential to make hard-earned money disappear in the blink of an eye. For instance, more than one-quarter of all biotech stocks are down by at least 10% over the trailing year despite a 20% gain in the S&P 500 over the comparable period.

Biotech investing: It sounds easy, but ...
One of the big variables that creates this gap in performance is that biotech investing relies on looking deep into the future more so than any other industry. Biotech companies are usually valued not for their revenue and profit/loss results from the prior quarter (which may not even exist if it's a clinical-stage biotech), a typical starting point for stock analysis with nearly all other industries, but instead are assessed based on the size of the patient pool their developing and existing drugs will treat, as well as the forecasted peak annual sales potential of those therapies.

It sounds so easy, but there are so many people who are unsuccessful biotech investors.

Three mistakes biotech investors make
Let's have a look at the three most common mistakes biotech investors make so you don't fall into the same trap, because, as these totals above show, if you do take advantage of the opportunities that the biotech sector offers your reward could be huge.

Mistake No. 1: Chasing penny stocks.
This mistake isn't confined just to the biotech sector, but the habit of chasing penny stocks is among the easiest ways to lose money investing in biotech stocks.


Source: David Goehring, Flickr

Inexperienced traders often forget that the price of a stock isn't what matters -- the market cap does. However, their eyes light up when they see a stock trading for just $1, $2, or $3 per share because they believe its "low price" gives it a better chance to double from its current level.

But stocks trading in the low single-digits are often there for a reason. For biotech stocks that are wholly clinical in nature that reason may require a little more digging, which is something short-term traders usually don't have the patience to do. But rest assured, a reason is almost always found.

Take Amarin (NASDAQ:AMRN) as a perfect example. Amarin has one drug approved by the Food and Drug Administration, Vascepa, for persons with really high triglyceride levels. Amarin tried to get Vascepa's indications expanded to cover a significantly larger portion of the population (those with triglyceride levels of between 200 mg/DL and 499 mg/DL) last year, but the FDA ultimately rejected this move. Though its share price below $2 may look tempting, especially considering that it's down by more than 65% over the past year, it remains to be seen if Amarin can generate the support from the FDA or the funds to eventually complete a costly and lengthy cardiovascular outcomes trials. And even if completed, investors have to wonder how many years it'd be before Amarin has a real shot at turning a profit. While its share price might give off a hint of undervaluation, the story behind the stock would merit a wise biotech investor to keeping distance.

Penny stocks also commonly have concerns about cash burn and/or dilution. When a biotech is in the clinical development stage it tends to burn through its cash on hand. This means investors are constantly wondering if their investment will have enough capital to not only finish its trials, but to simply survive. In order to maintain enough cash in the coffers to run its business many biotech stocks will turn to share offerings which do raise cash, but also come with the negative effect of diluting existing shareholders.

Mistake No: 2: Allowing emotions to get the better of you.
Secondly, far too many biotech investors allow their emotions to get the better of them, leaving them blinded to the long-term-growth drivers that they should really be focused on.


Source: Jazbeck, Flickr

A case in point here would be the weight control management sector and biotech stocks like VIVUS (NASDAQ:VVUS) and Arena Pharmaceuticals (NASDAQ:ARNA). Both VIVUS and Arena have a faithful following of supporters -- just check the comments section of any Motley Fool article if you need proof. Yet the overwhelming love for these stocks has left many of their shareholders blindsided by hefty losses in each stock. "Why?" you ask? Because investors were unwilling to believe there could be another side to their investing thesis.

As we've learned now after watching VIVUS' weight-loss drug Qsymia since it launched in 2012 and Arena/Eisai's Belviq since it launched in 2013, the demand for weight-loss therapies so far hasn't been that strong. Insurers have been slow to latch onto coverage and consumers simply haven't been willing to pay much, if at all, out of their own pocket to get their hands on these fat-busting drugs. With the possibility of even more competition on the horizon as a decision date from the FDA on Orexigen Therapeutics' Contrave nears, it would appear that the investing fervor surrounding the sector may be for naught.

Mistake No. 3: Not seeking pipeline diversity.
Lastly, far too many novice biotech investors focus on companies with very few existing drugs or that have just a handful of compounds in development. By doing this, investors are giving themselves only a limited chance of long-term success.


Source: Laffy4k, Flickr

Allow me to use a baseball analogy to better describe this. Imagine I asked you to hit a home run over the fence, but that you only get one pitch with which to do so. Now, imagine I have 20 baseballs in a bucket and I said you have to hit a single home run over the fence. In both scenarios you win if only one ball clears the fence. Which would you rather choose?

If you said the latter you're thinking like a true biotech investor because you're spreading your risk around over a number of developing and existing drugs. If a few developing compounds fail to succeed in clinical studies then your downside risk is mitigated by the fact there are more than a dozen other experimental compounds that might succeed. In contrast, a pipeline with only one or two drugs has the potential to blow up in biotech investors' faces if things don't go according to plan.

You can only grow more knowledgeable
Keep in mind that even if you avoid these common investing mistakes there are still no guarantees you'll succeed at biotech investing. But I'd certainly suggest that your chances of success will have gone way up by taking these points to heart.

If you think the biotech sector offers impressive growth potential, wait until you see the opportunity behind this revolutionary new technology.
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers